11th annual Inflammatory and Immune Diseases Drug Discovery and Development Summit 12-13 March 2007, San Francisco, USA.
The Strategic Research Institute (SRi) hosted the 11th International Inflammation and Immune Diseases Drug Discovery and Development World Summit in San Francisco during 12-13 March 2007. The summit comprised keynote sessions and two parallel tracks and focussed on targeting mechanisms for drug discovery and development, which modulate the immune response and which have anti-inflammatory activity in a number of human diseases. Indications included psoriasis, hepatitis C, allergic dermatitis, systemic lupus erythematosus, rheumatoid arthritis and osteoarthritis, multiple sclnerosis, cardiovascular disease and asthma. Data were presented supporting all stages of drug discovery from target identification and validation through to lead identification and optimisation to both early- and late-stage clinical development.
Braddock
Martin
M
Discovery Bioscience, AstraZeneca R&D Charnwood, Loughborough, Leicestershire, England, UK. Martin.Braddock@astrazeneca.com
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology; D001688:Biological Products; D015195:Drug Design; D000939:Epitopes / Q000276:immunology; D006801:Humans; D007154:Immune System Diseases / Q000276:immunology / Q000628:therapy*; D007155:Immunologic Factors / Q000627:therapeutic use*; D007167:Immunotherapy; D007249:Inflammation / Q000276:immunology / Q000628:therapy*; D012495:San Francisco
D000893:Anti-Inflammatory Agents; D001688:Biological Products; D000939:Epitopes; D007155:Immunologic Factors